Abstract
Greaves discusses a new study in PLoS Medicine that takes us closer to being able to adopt a pharmacogenetic approach to reduce bleeding risk from coumarin therapy.
Highlights
Warfarin and related coumarinbased anticoagulants are the mainstay of pharmacological management for the long-term prevention of thromboembolism
Coumarins inhibit the posttranslational carboxylation of glutamate residues on proteins dependent on vitamin K, including coagulation factors II, VII, IX, and X
The Perspectives section is for experts to discuss the clinical practice or public health implications of a published article that is freely available online
Summary
Warfarin and related coumarinbased anticoagulants are the mainstay of pharmacological management for the long-term prevention of thromboembolism. Despite recent advances in the development of novel, alternative, oral antithrombotics it is likely that coumarins will be used widely for at least the decade
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
